TheEdgeResearch
Home / Stocks / NTII

Neurobiological Technologies, Inc. (NTII)

OTC Healthcare Biotechnology
$0.00 ▲ +0.00%
Market Cap
$2,702
Sector
Healthcare
Industry
Biotechnology
Beta
6.95
52-Wk Range
0.000001-0.0001
CEO
John B. Stuppin
Country
US
Currency
USD

Neurobiological Technologies, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in EmeryVille, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2,702. On trailing twelve-month figures it carries a trailing P/E of 0.00, a net margin of 11.9%. Its beta of 6.95 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
0.00
Price / Sales
0.00
Price / Book
0.00
EV / EBITDA
-0.57
Gross margin
99.5%
Operating margin
13.2%
Net margin
11.9%
Return on equity
Debt / equity
0.00
Current ratio
35.34
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
4
IPO date
1994-10-31
Headquarters
EmeryVille, CA, US
About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. (NTII) is currently undergoing a liquidation and dissolution process, a plan that received stockholder endorsement in October 2009. In its earlier operations, the company's core focus was on the development of experimental pharmaceutical treatments for various human ailments. This firm, which was established in 1987, has its primary location in Emeryville, California.

Comparable companies

Neurobiological Technologies, Inc. is most often compared with the following Healthcare names:

ANTHCMRACOTQFFORUGBIMOVITPZRXQRBSHSNNAQSYVC
More research on NTII
NTII technical analysis NTII TheEdge Score Compare against peers
Open full interactive analysis & DCF →